U.K. industry reiterates Brexit concerns

The Association of the British Pharmaceutical Industry (ABPI) highlighted that its primary concerns around a "no-deal" Brexit include the continuity of the pharmaceutical supply chain and sharing of data between the U.K. and European regulatory authorities. The bodies have yet to agree on specifics of a long-term cooperation regarding the regulation, trade and supply of medicines following U.K's exit from the union.

In oral testimony before the U.K. Parliament's Exiting the European Union Commons Select Committee, ABPI's CEO Mike Thompson told MPs that while U.K. industry is preparing for a "no-deal" Brexit by stockpiling essential medicines, concerns remain around whether available storage is sufficient to stockpile biologics, which require temperature-controlled environments. Thompson added that should no deal be reached between the U.K. and the EU, a customs border might be put in place. This would raise additional concerns about the logistics of efficiently transporting medicines to and from the continent, as 45 million packs of medicines move from the U.K. to the EU every month, 90% of which go through the single port of Calais, France...